The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates
- PMID: 35290049
- PMCID: PMC9026740
- DOI: 10.1021/acs.jmedchem.1c02040
The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates
Abstract
Interfering with the self-assembly of virus nucleocapsids is a promising approach for the development of novel antiviral agents. Applied to hepatitis B virus (HBV), this approach has led to several classes of capsid assembly modulators (CAMs) that target the virus by either accelerating nucleocapsid assembly or misdirecting it into noncapsid-like particles, thereby inhibiting the HBV replication cycle. Here, we have assessed the structures of early nucleocapsid assembly intermediates, bound with and without CAMs, using molecular dynamics simulations. We find that distinct conformations of the intermediates are induced depending on whether the bound CAM accelerates or misdirects assembly. Specifically, the assembly intermediates with bound misdirecting CAMs appear to be flattened relative to those with bound accelerators. Finally, the potency of CAMs within the same class was studied. We find that an increased number of contacts with the capsid protein and favorable binding energies inferred from free energy perturbation calculations are indicative of increased potency.
Conflict of interest statement
Conflict of Interest Disclosure
Drs. Schinazi, Amblard and Bassit along with Emory University are entitled to equity and royalties related to products licensed to Aligos Therapeutics, Inc. being further evaluated in the research described in this paper. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies.
Figures






References
-
- Schweitzer A; Horn J; Mikolajczyk RT; Krause G; Ott JJ Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015, 386, 1546–1555. - PubMed
-
- Deres K; Schröder CH; Paessens A; Goldmann S; Hacker HJ; Weber O; Krämer T; Niewöhner U; Pleiss U; Stoltefuss J; Graef E; Koletzki D; Masantschek RNA; Reimann A; Jaeger R; Gross R; Beckermann B; Schlemmer K-H; Haebich D; Rübsamen-Waigmann H Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299, 893–896. - PubMed
-
- Feld JJ; Colledge D; Sozzi V; Edwards R; Littlejohn M; Locarnini SA The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 2007, 76, 168–177. - PubMed